Symptomatic malignant spinal cord compression in children: a single-center experience.
Extramedullary
Intradural
Intramedullary
Motor deficit
Pain
Sphincter dysfunction
Spinal cord compression
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
12 Jul 2019
12 Jul 2019
Historique:
received:
08
04
2019
accepted:
20
06
2019
entrez:
14
7
2019
pubmed:
14
7
2019
medline:
18
1
2020
Statut:
epublish
Résumé
Malignant spinal cord compression (MSCC) is associated withpoor prognosis and may lead to permanent paralysis, sensory loss, and sphincter dysfunction. Very limited data are available on incidence and etiology of MSCC in pediatric population. We aimed to examine etiology, clinical presentation and treatment of pediatric patient with MSCC admitted to the Santobono-Pausilipon Children's Hospital, Naples, Italy. Forty-four children under 18 yearsadmitedsince 2007 and assessed for MSCC clinical presentations, evaluation, and treatment.were retrospectively collected from our institutional pediatric oncology and neurosurgery database. The median age at time of MSCC diagnosis was 52 months, with a peak in young (≤3 years) patients. The leading cause of MSCC was extramedullary tumors (63.6%), in particular neuroblastoma (27.2%) followed by Ewing sarcomas (15.9%). Cord compression was the presenting feature of a new malignancy in 33 (75%) patients, and a consequence of metastatic disease progression or relapse in the remaining 11 (25%) patients. Motor deficit was the initial symptoms of spinal compression in all patients, while pain was present in about 60% of patients, followed by sphincteric deficit (43.2%). The primary tumor site was located in the neck in 3 (6.8%) patients, thorax in 16 (36.4%), cervico-thoracic region in 3 (6.8%), thoraco-lumbar region in 8 (18.2%), abdomen in 5 (11.4%), lumbar-sacral region in 7 (15.9%) and thoracic-lumbar-sacral region in 1 (2.3%). The median length of the interval between symptom onset and tumor diagnosis varied widely from 0 to 360 days in the entire population, however this interval was significantly shorter in patients with known neoplasia in comparisonto patients with new diagnosis (at relapse 7 days [interquartile range 3-10] vs at diagnosis 23 days [7-60]). Pre and post-operative spine magnetic resonance imagingwas performed in all cases, and most(95%) patients underwent neurosurgical treatment as first treatment. Severe motor deficit was associated with younger age and severe motor deficit at diagnosis was associated withworst motor outcomes at discharge from neurosurgery. Patients with progression or relapsed disease showed a worst prognosis, while the majority of patients (70.5%) were alive at 5 years after diagnosis. The natural history of MSCC in children is associated to permanent paralysis, sensory loss, and sphincter dysfunction, thus prompt diagnosis and correct management are needed to minimize morbidity. Treatment strategies differed widely among cancer types and study groups in the absence of optimal evidence-based treatment guidelines. When the diagnosis is uncertain, surgery provides an opportunity to biopsy the lesion in addition to treating the mass.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant spinal cord compression (MSCC) is associated withpoor prognosis and may lead to permanent paralysis, sensory loss, and sphincter dysfunction. Very limited data are available on incidence and etiology of MSCC in pediatric population. We aimed to examine etiology, clinical presentation and treatment of pediatric patient with MSCC admitted to the Santobono-Pausilipon Children's Hospital, Naples, Italy.
METHODS
METHODS
Forty-four children under 18 yearsadmitedsince 2007 and assessed for MSCC clinical presentations, evaluation, and treatment.were retrospectively collected from our institutional pediatric oncology and neurosurgery database.
RESULTS
RESULTS
The median age at time of MSCC diagnosis was 52 months, with a peak in young (≤3 years) patients. The leading cause of MSCC was extramedullary tumors (63.6%), in particular neuroblastoma (27.2%) followed by Ewing sarcomas (15.9%). Cord compression was the presenting feature of a new malignancy in 33 (75%) patients, and a consequence of metastatic disease progression or relapse in the remaining 11 (25%) patients. Motor deficit was the initial symptoms of spinal compression in all patients, while pain was present in about 60% of patients, followed by sphincteric deficit (43.2%). The primary tumor site was located in the neck in 3 (6.8%) patients, thorax in 16 (36.4%), cervico-thoracic region in 3 (6.8%), thoraco-lumbar region in 8 (18.2%), abdomen in 5 (11.4%), lumbar-sacral region in 7 (15.9%) and thoracic-lumbar-sacral region in 1 (2.3%). The median length of the interval between symptom onset and tumor diagnosis varied widely from 0 to 360 days in the entire population, however this interval was significantly shorter in patients with known neoplasia in comparisonto patients with new diagnosis (at relapse 7 days [interquartile range 3-10] vs at diagnosis 23 days [7-60]). Pre and post-operative spine magnetic resonance imagingwas performed in all cases, and most(95%) patients underwent neurosurgical treatment as first treatment. Severe motor deficit was associated with younger age and severe motor deficit at diagnosis was associated withworst motor outcomes at discharge from neurosurgery. Patients with progression or relapsed disease showed a worst prognosis, while the majority of patients (70.5%) were alive at 5 years after diagnosis.
CONCLUSIONS
CONCLUSIONS
The natural history of MSCC in children is associated to permanent paralysis, sensory loss, and sphincter dysfunction, thus prompt diagnosis and correct management are needed to minimize morbidity. Treatment strategies differed widely among cancer types and study groups in the absence of optimal evidence-based treatment guidelines. When the diagnosis is uncertain, surgery provides an opportunity to biopsy the lesion in addition to treating the mass.
Identifiants
pubmed: 31300063
doi: 10.1186/s13052-019-0671-5
pii: 10.1186/s13052-019-0671-5
pmc: PMC6626347
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Références
J Clin Oncol. 2001 Jan 1;19(1):183-90
pubmed: 11134211
Pediatr Hematol Oncol. 2003 Sep;20(6):457-66
pubmed: 14631620
J Neurosurg. 1991 Jan;74(1):70-5
pubmed: 1845814
Childs Nerv Syst. 2009 Jan;25(1):63-9
pubmed: 18843494
Spinal Cord. 2010 Feb;48(2):118-21
pubmed: 19806161
Hematol Oncol Clin North Am. 2010 Jun;24(3):537-51
pubmed: 20488352
Dev Med Child Neurol. 2012 Apr;54(4):347-52
pubmed: 22329756
Spinal Cord. 2014 Feb;52(2):123-32
pubmed: 23295473
J Pediatr Hematol Oncol. 2013 Apr;35(3):232-6
pubmed: 23511492
Spine (Phila Pa 1976). 2013 Jun 15;38(14):E878-82
pubmed: 23574815
Eur J Paediatr Neurol. 2013 Nov;17(6):620-4
pubmed: 23806995
Pediatr Blood Cancer. 2014 Aug;61(8):1369-75
pubmed: 24619960
Neurosurgery. 2015 Nov;77(5):718-24; discussion 724-5
pubmed: 26308634
Phys Med Rehabil Clin N Am. 2017 Feb;28(1):101-114
pubmed: 27912991
Pediatr Blood Cancer. 2017 Aug;64(8):null
pubmed: 28150396
Top Spinal Cord Inj Rehabil. 2017 Summer;23(3):279-284
pubmed: 29339904
Pediatrics. 1986 Sep;78(3):438-43
pubmed: 3748677
J Pediatr. 1984 Feb;104(2):221-4
pubmed: 6694014